GT Biopharma, Inc.
GTBP
$2.35
$0.062.62%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -73.25% | -20.84% | 22.68% | 38.51% | 63.62% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 83.21% | 97.55% | -97.56% | -126.41% | -140.23% |
| Change in Net Operating Assets | -57.53% | -100.02% | -148.72% | 154.75% | 191.75% |
| Cash from Operations | -45.77% | -12.43% | 2.88% | 21.68% | 41.83% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 741.76% | 166.39% | 375.65% | 517.01% | -116.54% |
| Cash from Investing | 741.76% | 166.39% | 375.65% | 517.01% | -116.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -52.52% | -52.52% | -52.52% | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -52.52% | -52.51% | -52.51% | -100.00% | 2,898.21% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 164.55% | 2,010.93% | 350.17% | 98.19% | -39.35% |